TD Asset Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

TD Asset Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-57,513	Closed	-$1.54M	–	1530
2022 Q1	$1.54M	Sell	57,513 -22,190	-28%	-$746K	﹤0.01%	1160
2021 Q4	$3.8M	Buy	79,703 +23,094	+41%	+$1.03M	﹤0.01%	947
2021 Q3	$3.76M	Buy	56,609 +5,600	+11%	+$399K	﹤0.01%	902
2021 Q2	$3.25M	Sell	51,009 -1,151	-2%	-$85.1K	﹤0.01%	943
2021 Q1	$4.93M	Buy	52,160 +4,119	+9%	+$490K	0.01%	830
2020 Q4	$5.85M	Buy	48,041 +12,573	+35%	+$1.38M	0.01%	749
2020 Q3	$3.1M	Hold	35,468	–	–	﹤0.01%	823
2020 Q2	$2.29M	Buy	35,468 +5,664	+19%	+$327K	﹤0.01%	846
2020 Q1	$1.33M	Buy	29,804 +3,200	+12%	+$170K	﹤0.01%	925
2019 Q4	$1.66M	Buy	26,604 +3,325	+14%	+$158K	﹤0.01%	970
2019 Q3	$875K	Buy	+23,279	New	+$1.01M	﹤0.01%	1080

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

TD Asset Management's TPTX Position: Q2 2022 in Review

TD Asset Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 57,513 shares — an estimated $1.54M sold.

TD Asset Management first reported a position in TPTX in Q3 2019 and held it in 11 quarters. The position peaked at $5.85M in Q4 2020. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

TD Asset Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
TD Asset Management sold 57,513 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $1.54M.
TD Asset Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
TD Asset Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $5.85M in Q4 2020.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on TD Asset Management's 13F filing for Q2 2022, filed 4 Aug 2022.